A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ABIONYX PHARMA operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.6M | 4.6M | 4.9M | 5.0M | 5.5M | - |
| Net Income | -6.3M | -6.3M | -4.7M | -3.8M | -4.4M | -6.9M |
| EPS | $-0.18 | $-0.18 | $-0.14 | $-0.13 | $-0.16 | $-0.27 |
| Free Cash Flow | -3.6M | -3.6M | -4.0M | -4.1M | -3.7M | -8.1M |
| ROIC | -441.5% | -97.1% | -54.8% | -43.8% | -47.3% | -187.9% |
| Gross Margin | 13.1% | 13.1% | 18.5% | 13.3% | 12.1% | - |
| Debt/Equity | 0.00 | 0.54 | 0.15 | 0.38 | 0.27 | 0.41 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -6.3M | -6.3M | -4.8M | -3.7M | -4.3M | -7.0M |
| Operating Margin | -136.3% | -136.3% | -98.1% | -73.5% | -78.2% | - |
| ROE | -123.0% | -95.0% | -56.6% | -47.3% | -44.0% | -68.0% |
| Shares Outstanding | 35M | 35M | 34M | 29M | 28M | 25M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0 | 0 | N/A | 5.5M | 5.0M | 4.9M | 4.6M | 4.6M |
| Gross Margin | N/A | N/A | N/A | 12.1% | 13.3% | 18.5% | 13.1% | 13.1% |
| R&D | -833K | -1.9M | -4.5M | -1.2M | -1.6M | -2.1M | -1.7M | -1.7M |
| SG&A | -2.0M | -1.5M | -2.8M | -3.9M | -2.8M | -3.7M | -5.2M | -5.2M |
| EBIT | -2.8M | -3.4M | -7.0M | -4.3M | -3.7M | -4.8M | -6.3M | -6.3M |
| Op. Margin | N/A | N/A | N/A | -78.2% | -73.5% | -98.1% | -136.3% | -136.3% |
| Net Income | 2.1M | -2.2M | -6.9M | -4.4M | -3.8M | -4.7M | -6.3M | -6.3M |
| Net Margin | N/A | N/A | N/A | -80.1% | -75.8% | -96.3% | -136.6% | -136.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -24.1% | -22.8% | -187.9% | -47.3% | -43.8% | -54.8% | -97.1% | N/M |
| ROE | 27.7% | -28.7% | -68.0% | -44.0% | -47.3% | -56.6% | -95.0% | -123.0% |
| ROA | 18.0% | -18.6% | -36.6% | -20.9% | -23.3% | -30.8% | -42.6% | -42.3% |
| Cash Flow | ||||||||
| Op. Cash Flow | 4.4M | -688K | -7.9M | -3.5M | -4.0M | -3.9M | -3.3M | -3.3M |
| Free Cash Flow | 4.4M | -806K | -8.1M | -3.7M | -4.1M | -4.0M | -3.6M | -3.6M |
| Owner Earnings | 4.4M | -800K | -8.9M | -4.2M | -4.2M | -4.7M | -4.4M | -4.4M |
| CapEx | 0 | 118K | 196K | 174K | 113K | 73K | 274K | 274K |
| Maint. CapEx | 0 | 0 | 0 | 142K | 166K | 146K | 143K | 143K |
| Growth CapEx | N/A | N/A | N/A | 32K | 0 | 0 | 131K | 131K |
| D&A | 0 | 0 | 0 | 142K | 166K | 146K | 143K | 143K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 30K | 77K | 29K | 39K | 63K | 0 | 0 |
| Buyback Yield | 0.0% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | 113K | 962K | 533K | 22K | 676K | 897K | 897K |
| Debt Repayment | 448K | 230K | 22K | 248K | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -8.1M | -10M | -4.2M | -2.3M | -1.2M | -2.3M | -1.3M | -4.0M |
| Cash & Equiv. | 9.3M | 11M | 9.4M | 4.3M | 4.5M | 3.5M | 4.0M | 4.0M |
| Long-Term Debt | 0 | N/A | N/A | 1.5M | N/A | 660K | 2.2M | 2.2M |
| Debt/Equity | 0.17 | 0.01 | 0.41 | 0.27 | 0.38 | 0.15 | 0.54 | 0.00 |
| Interest Coverage | -5.7 | -26.3 | -33.6 | -15.7 | -11.3 | -33.8 | -34.8 | -34.8 |
| Equity | 7.5M | 7.6M | 13M | 7.5M | 8.6M | 8.1M | 5.1M | 5.1M |
| Total Assets | 11M | 12M | 26M | 17M | 16M | 15M | 15M | 15M |
| Total Liabilities | 4.0M | 4.2M | 13M | 9.1M | 7.5M | 6.5M | 9.7M | 9.7M |
| Intangibles | N/A | N/A | N/A | 79K | N/A | 83K | 75K | 75K |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 7.5M | 7.4M | 7.4M | 2.6M | 3.2M | 2.3M | 344K | 344K |
| Current Assets | 11M | 12M | 15M | 8.0M | 7.5M | 6.3M | 6.2M | 6.2M |
| Current Liabilities | 3.9M | 4.1M | 8.0M | 5.4M | 4.3M | 4.0M | 5.8M | 5.8M |
| Per Share Data | ||||||||
| EPS | 0.10 | -0.09 | -0.27 | -0.16 | -0.13 | -0.14 | -0.18 | -0.18 |
| Owner EPS | 0.22 | -0.03 | -0.35 | -0.15 | -0.14 | -0.14 | -0.13 | -0.13 |
| Book Value | 0.36 | 0.32 | 0.50 | 0.27 | 0.29 | 0.24 | 0.15 | 0.15 |
| Cash Flow/Share | -0.22 | -0.03 | -0.31 | -0.13 | -0.14 | -0.12 | -0.10 | -0.18 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 20.5M | 23.6M | 25.3M | 28.0M | 29.3M | 33.7M | 34.7M | 34.7M |
| Valuation | ||||||||
| P/E Ratio | 3.6 | -11.5 | -10.1 | -12.0 | -10.9 | -8.9 | -22.7 | -19.8 |
| P/FCF | 1.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 1.0 | 3.3 | 5.5 | 7.0 | 4.9 | 5.2 | 27.9 | 24.4 |
| Price/Sales | N/A | N/A | N/A | 9.6 | 8.3 | 8.6 | 31.0 | 27.1 |
| FCF Yield | 59.0% | -3.2% | -11.6% | -7.0% | -9.9% | -9.5% | -2.5% | -2.9% |
| Market Cap | 7.5M | 25M | 70M | 53M | 42M | 42M | 143M | 125M |
| Avg. Price | 0.42 | 0.89 | 1.46 | 2.07 | 1.65 | 1.30 | 2.48 | 3.60 |
| Year-End Price | 0.36 | 1.06 | 2.75 | 1.89 | 1.42 | 1.26 | 4.11 | 3.60 |
ABIONYX PHARMA passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 14.3%. At current prices, the estimated annualized return to fair value is -25.0%.
ABIONYX PHARMA (ABNX-PA) has a 5-year average return on invested capital (ROIC) of -86.2%. This is below average and may indicate limited pricing power.
ABIONYX PHARMA (ABNX-PA) has a market capitalization of $125M. It is classified as a small-cap stock.
ABIONYX PHARMA (ABNX-PA) does not currently pay a regular dividend.
ABIONYX PHARMA (ABNX-PA) operates in the Biotechnology industry, within the Healthcare sector.
ABIONYX PHARMA (ABNX-PA) reported annual revenue of $5 million in its most recent fiscal year, based on SEC EDGAR filings.
ABIONYX PHARMA (ABNX-PA) has a net profit margin of -136.6%. The company is currently unprofitable.
ABIONYX PHARMA (ABNX-PA) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ABIONYX PHARMA (ABNX-PA) has a debt-to-equity ratio of 0.54. This indicates moderate leverage.
ABIONYX PHARMA (ABNX-PA) reported earnings per share (EPS) of $-0.18 in its most recent fiscal year.
ABIONYX PHARMA (ABNX-PA) has a return on equity (ROE) of -95.0%. A negative ROE may indicate losses or negative equity.
ABIONYX PHARMA (ABNX-PA) has a 5-year average gross margin of 14.3%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 7 years of financial data for ABIONYX PHARMA (ABNX-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ABIONYX PHARMA (ABNX-PA) has a book value per share of $0.15, based on its most recent annual SEC filing.